Ifabotuzumab (KB004) is an IgG1κ antibody targeting Significantly reduced droxyproline to levels and IL-6 transcript levels.
Significantly reduced the total number of CCR10+EphA3+, as well as Lin-CCR10+ cells.
[1]. Hohmann MS, et al. Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF. JCI Insight. 2021 Jun 8;6(11):e141061.
[2]. Swords R T,et al. KB004, a novel non-fucosylated humaneered® antibody, targeting EphA3, is active and well tolerated in a phase I/II study of advanced hematologic malignancies[J]. Blood, 2014, 124(21): 3756.
















